Pharma giant Novartis has shed five of its ophthalmic drugs, with Harrow Health agreeing to purchase the exclusive United States commercial rights for up to $US175 million.
Novartis will still own the drugs outside the US.
The US deal includes the exclusive US rights to cataract surgery recovery eyedrops Ilevro and Nevanac, bacterial conjunctivitis eyedrop Vigamox, inflammation eye drops Maxidex and the injectable Triesence.
The sale, expected to close early 2023, is part of a continuing push by Novartis to downsize in ophthalmology.
